 ERYTECH Pharma Nasdaq Euronext: ERYP, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided an update on the ongoing Phase 2 trial, sponsored by the Nordic Society of Paediatric Haematology and Oncology NOPHO of eryaspase in second-line acute lymphoblastic leukemia ALL patients. The NOR-GRASPALL-2016 trial is evaluating the safety and activity of eryaspase in primarily pediatric acute lymphoblastic leukemia ALL patients who developed hypersensitivity reactions to pegylated asparaginase. 